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Background: This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic
ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site
Occurrence (SSO).
Methods: Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical
procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and
Quality of Life at 1, 3, 6, 12, 18, and 24-months.
Results: 120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m2 received P4HBST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%),
diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%),
hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary
ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients
underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm2,
mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring
intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) devicerelated adverse events (excluding recurrence).
Conclusion: P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved
quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher
than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high
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in defects ≥7.1 cm2 (43.3%) compared to defects <7.1 cm2 (18.6%). Thus, in LVIHR, P4HB-ST may be better
suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger
defects until additional studies can further investigate outcomes.

1. Introduction

concentration ≥2.5 mg/dL). The study was designed to treat 120 pa
tients at approximately 16 sites throughout the United States. In
vestigators were chosen due to experience with minimally invasive
hernia repair techniques. Specific training was not required based on the
similarity in technique required for P4HB-ST mesh compared to other
meshes. The protocol was approved by the Institutional Review Board
(IRB) at each institution, and all subjects provided informed consent
prior to enrollment. Recruitment occurred between May 4, 2016 and
November 27, 2017 through the surgical offices of the Investigators
according to the eligibility criteria.

Biomaterials have been utilized to repair incisional hernias for more
than half a century [1]. Permanent synthetic materials were among the
first such biomaterials and continue to be the gold standard for inci
sional hernia repair [2]. With the advent of laparoscopic surgery,
intraabdominal mesh placement became routine, necessitating the
development of new devices commonly described as “composites” [3,4].
Devices in this broad category are comprised of a structural mesh
combined with a barrier layer that is intended to minimize tissue
attachment between the abdominal viscera and the mesh. Both the un
derlying structural mesh and the barrier can be comprised of a variety of
materials, including permanent synthetic polymers, biological
tissue-derived materials, and absorbable polymers [3–5].
As described by the Deeken & Lake Mesh Classification System in a
recent review article, a multitude of possible combinations exist, with 7
sub-categories of “barrier” devices encompassing more than 40 designs
[5]. One particularly novel design is P4HB-ST mesh (Phasix™ ST Mesh,
C. R. Bard/Davol, Inc., Warwick, RI), which represents the only fully
absorbable barrier mesh construct. P4HB-ST mesh is comprised of an
absorbable polymer scaffold of poly-4-hydroxybutyrate (P4HB) com
bined with an absorbable hydrogel barrier layer (ST) of sodium hya
luronate, carboxymethylcellulose, and polyethylene glycol [6]. The
barrier is absorbed over a period of approximately 30 days, while the
underlying P4HB scaffold is absorbed by 12–18 months [6]. The pre
dictable absorption of the components results in a gradual transfer of
load from the mesh back to the remodeled abdominal wall. The
medium-term absorption profile of P4HB meshes (Phasix™ Mesh &
Phasix™ ST Mesh: 12–18 months) [6,7] provides support to the repair
site longer than short-term absorbable materials such as glycolide:lac
tide (Vicryl®: 2–3 months) [8] and polyglycolic acid:trimethylene car
bonate (Bio-A®: 6–7 months) [9]. This is an important benefit since a
mesh that is absorbed before newly deposited host collagen has matured
may result in a hernia recurrence due to a lack of mechanical support at
the repair site.
There have been favorable long-term outcomes reported with P4HB
mesh in open cases [10,11]. However, there have been no reports on
clinical outcomes when used in a minimally invasive manner. The
purpose of this study is to evaluate P4HB-ST mesh in minimally invasive
hernia repair in Class I (clean) wounds at high risk for SSO, and repre
sents the first clinical trial of P4HB-ST. Patients at high risk for SSO were
chosen to allow comparison with prior studies of P4HB mesh without the
ST layer.

2.2. Inclusion/exclusion criteria
Patients with a diagnosis of ventral or abdominal incisional hernia
with a planned laparoscopic/robotic surgical repair with defect closure
were screened for study eligibility against the study protocol inclusion
and exclusion criteria. Patients were included in the study if they were
18 years of age or older, met the criteria for a Class I (clean) wound as
defined by the CDC [12], had one or more of the comorbidities listed
above, were willing to undergo laparoscopic hernia repair with intra
abdominal placement of P4HB-ST mesh, and provided written informed
consent.
Patients were excluded if they had four or more previous hernia
repairs of the index hernia, a hernia defect greater than 350 cm2,
existing mesh in the affected area that could not be removed, permanent
mesh adjacent to the current hernia, planned preperitoneal approach, a
known collagen disorder, peritonitis, on or may be placed on chemo
therapy medications during the study period, BMI >40 kg/m2, cirrhosis
of the liver and/or ascites, American Society of Anesthesiology Class 4 or
5, life expectancy <2 years, surgical wound classified as Class II (cleancontaminated), Class III (contaminated), or Class IV (dirty-contami
nated) as defined by the CDC [12], active or latent systemic infection,
contraindication to placement of mesh, planned bridge repair, pregnant
or plans to become pregnant during the study period, enrolled in another
interventional clinical study within the last 30 days, part of the study site
personnel directly involved with the study, known allergy to the test
device or component materials, or any condition that, in the opinion of
the investigator, would preclude the use of the study device or preclude
the patient from completing the follow-up requirements.
2.3. Surgical technique
All patients underwent laparoscopic or robotic ventral hernia repair
with preoperative antibiotics administered according to hospital pro
tocol. Intraoperative exclusion criteria (i.e., hernia >350 cm2, Class II,
III, or IV wounds, latent or systemic infection, peritonitis, and bridge
repair technique) were evaluated and recorded, and patients were
screen-failed when applicable. The hernia defect was closed by reap
proximating the fascia, including myofascial release (MR), if needed.
Bridged repairs were not allowed according to the protocol, and the
method of fascial closure was left up to the individual investigators.
Patients that met the inclusion criteria received intraabdominal place
ment of P4HB-ST mesh. The prosthesis was positioned with its edges
extending beyond the margins of the defect by at least 5 cm, and the
coated side was oriented against the bowel. Fixation devices were
applied around the periphery of the mesh at approximately 1–2 cm in
tervals, and the trocar sites were closed with sutures and/or staples.
Wounds were dressed with sterile occlusive dressings, and postoperative
care was performed consistent with surgeon practice at each site.

2. Materials and methods
2.1. Study design
The objective of this prospective, multicenter, single-arm, open-label
study (ClinicalTrials.gov/NCT02712398) was to assess the safety, per
formance, and effectiveness of P4HB-ST mesh (Phasix™ ST Mesh, C. R.
Bard, Inc., Warwick, RI) in laparoscopic/robotic ventral or incisional
hernia repair (LVIHR) in a cohort at high risk for surgical site occur
rences (SSO). Patients were considered at high risk for SSO with one or
more of the following comorbid conditions: body mass index (BMI)
between 30 and 40 kg/m2(inclusive), active smokers, chronic obstruc
tive pulmonary disease (COPD), diabetes mellitus, immunosuppression,
coronary artery disease, chronic corticosteroid use (>6 months systemic
use), hypo-albuminemia (preoperative serum albumin <3.4 g/dL),
advanced age (≥75 years), or renal insufficiency (serum creatinine
2
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2.4. Data collection

3. Results

Surgical details, including procedure date, start/stop times, hernia
defect size, mesh size, repair technique, concomitant procedures,
adverse events, and procedure-related complications were documented.
Follow-up visits were scheduled for 1, 3, 6, 12, 18, and 24 months
postoperatively. At each visit, Quality of Life assessments, device-related
adverse events, hernia recurrence, concomitant pain medication usage,
and surgical complications were documented.

3.1. Patient demographics
As shown in Fig. 1, a total of n = 143 patients were enrolled in the
trial. Eighteen (n = 18) patients were excluded after the screening
process, while n = 125 met all of the initial screening criteria. Of those n
= 125 patients, a total of n = 120 patients were ultimately implanted
with P4HB-ST mesh. As shown in Table 1, the patients had a mean age of
55.0 ± 14.9 years and BMI of 33.2 ± 4.5 kg/m2. Slightly more than half
of the patients were male (n = 63, 52.5%), and the majority were White
(n = 110, 91.7%). A small minority of patients experienced a prior repair
of the index hernia (n = 22, 18.3%). Patient-reported comorbid condi
tions included: obesity (104/120, 86.7%), active smoker (54/120,
45.0%), diabetes (20/120, 16.7%), advanced age (12/120, 10.0%),
coronary artery disease (9/120, 7.5%), COPD (6/120, 5.0%), immuno
suppression (3/120, 2.5%), chronic corticosteroid use (3/120, 2.5%),
hypoalbuminemia (1/120, 0.8%), and renal insufficiency (1/120,
0.8%). The majority of patients had 1 or 2 comorbidities (n = 104,
86.7%), with a minority reporting 3 or more comorbidities (n = 16,
13.3%).

2.5. Study endpoints
The primary endpoint of the study was Surgical Site Occurrence
(SSO) requiring intervention within 45 days postimplantation, including
Surgical Site Infection (SSI), seroma, hematoma, wound dehiscence, skin
necrosis, mesh infection and fistula. This timeframe was chosen as most
SSOs occur in the early postoperative period, and it was desirable to
assess SSOs during the period in which the ST barrier was still intact.
Secondary endpoints included: surgical procedure time, length of stay,
SSO >45 days postimplantation, hernia recurrence rate, device-related
adverse events, rate of reoperation of the index hernia repair, and
Quality of Life assessments (Visual Analog Scale for pain, Carolinas
Comfort Scale®, and SF-12v2®), assessed at 1, 3, 6, 12, 18, and 24months.

3.2. Preoperative data
As shown in Table 1, hernia types included primary ventral (53/120,
44.2%), primary incisional (45/120, 37.5%), recurrent ventral (7/120,
5.8%), and recurrent incisional (15/120, 12.5%). The majority of her
nias were umbilical (n = 92, 76.7%), with epigastric, infraumbilical,
suprapubic, subxiphoid, and “other” comprising the remaining hernia
locations.

2.6. Statistical analysis
GraphPad Prism 6.01 statistical software was utilized to generate
descriptive statistics. Frequency counts and percentages are reported for
categorical variables, while mean and standard deviation are reported
for continuous variables. Hernia recurrence is reported via Kaplan-Meier
estimates. Quality of life assessments were evaluated for statistical sig
nificance between baseline values and 24-month values using an un
paired, two-tailed t-test with Welch’s correction (p < 0.05 statistically
significant). This work complies with the STROCSS criteria (Strength
ening the Reporting of Cohort Studies in Surgery) [13].

3.3. Perioperative data
Patients underwent minimally invasive hernia repair via laparo
scopic (67/120, 55.8%) or robotic-assisted technique (53/120, 44.2%)
with a mean defect size of 4.6 ± 3.8 cm length, 3.3 ± 2.5 cm width, and
15.7 ± 28.3 cm2 area (Table 2). A number of defects were described as
“Swiss cheese” (n = 22, 18.3%). An intraabdominal technique without
myofascial release (MR) was utilized in the majority of patients (n =
118, 98.3%). However, in n = 2 (1.7%) patients, MR was performed via

Fig. 1. Flow of patients throughout the study period.
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Table 1
Preoperative data: Patient demographics and hernia data.
Patients treated with P4HB-ST mesh, n

120

Patients with 24-month follow-up, n (%)
Sex
Male, n (%)
Female, n (%)
Race
Asian, n (%)
Black, n (%)
White, n (%)
Biracial, n (%)
Not reported, n (%)
Age (years), mean ± SD
Body mass index, kg/m2 (mean ± SD)
Patients with prior repairs to index hernia
0 prior repairs, n (%)
1 prior repairs, n (%)
2 prior repairs, n (%)
3 prior repairs, n (%)
Number of Comorbidities
1 Comorbidity, n (%)
2 Comorbidities, n (%)
3 Comorbidities, n (%)
4 Comorbidities, n (%)
Comorbidities
Obesity, n (%)
Active smoker, n (%)
Diabetes, n (%)
Advanced age, n (%)
Coronary artery disease, n (%)
COPD, n (%)
Immunosuppressed, n (%)
Chronic corticosteroid use, n (%)
Hypoalbuminemia, n (%)
Renal insufficiency, n (%)
Hernia Diagnosis
Primary ventral, n (%)
Primary incisional, n (%)
Recurrent ventral, n (%)
Recurrent incisional, n (%)
Hernia Location
Umbilical, n (%)
Epigastric, n (%)
Infraumbilical, n (%)
Suprapubic, n (%)
Subxiphoid, n (%)
Other, n (%)

83 (69.2%)

Table 2
Perioperative data: Mesh/defect sizes and surgical technique (MR = myo
fascial release).
Type of Procedure
Laparoscopic only, n (%)
Robotic-assisted, n (%)
Surgical Technique
Intraabdominal without MR, n (%)
Intraabdominal with MR, n (%)
Defect
Length, cm (mean ± SD)
Width, cm (mean ± SD)
Area, cm2 (mean ± SD)
Swiss Cheese Defect, n (%)
Mesh
Length, cm (mean ± SD)
Width, cm (mean ± SD)
Area, cm2 (mean ± SD)
Area Ratio, mean ± SD
Fixation
Fixation spacing, cm (mean ± SD)
Suture & Mechanical, n (%)
Suture only, n (%)
Mechanical only, n (%)
Drains
0 drains, n (%)
1 drain, n (%)
≥2 drains, n (%)

63 (52.5%)
57 (47.5%)
1 (0.8%)
7 (5.8%)
110 (91.7%)
1 (0.8%)
1 (0.8%)
55.0 ± 14.9
33.2 ± 4.5
98 (81.7%)
19 (15.8%)
2 (1.7%)
1 (0.8%)
48 (40.0%)
56 (46.7%)
11 (9.2%)
5 (4.2%)
104 (86.7%)
54 (45.0%)
20 (16.7%)
12 (10.0%)
9 (7.5%)
6 (5.0%)
3 (2.5%)
3 (2.5%)
1 (0.8%)
1 (0.8%)

67 (55.8%)
53 (44.2%)
118 (98.3%)
2 (1.7%)
4.6±3.8
3.3±2.5
15.7±28.3
22 (18.3%)
16.0±4.3
14.3±3.3
182.6±74.9
34.6±35.6
1.2±1.2
52 (43.3%)
35 (29.2%)
33 (27.5%)
115 (95.8%)
2 (1.7%)
3 (2.5%)

Table 3
Primary & secondary study endpoints (p < 0.05 compared to Baseline).

53 (44.2%)
45 (37.5%)
7 (5.8%)
15 (12.5%)
92 (76.7%)
24 (20.0%)
13 (10.8%)
6 (5.0%)
4 (3.3%)
4 (3.3%)

endoscopic/minimally invasive (MIS) technique. All defects were rein
forced with P4HB-ST mesh with a mean length of 16.0 ± 4.3 cm, width
of 14.3 ± 3.3 cm, and area of 182.6 ± 74.9 cm2. Fixation devices were
spaced an average of 1.2 ± 1.2 cm around the periphery of the mesh. A
variety of fixation devices were used, ranging from suture, mechanical
fixation, or a combination of suture and mechanical fixation. No delib
erately bridged repairs were performed. However, the investigators
closed the fascia using their own selected technique, and a variety of
fascial closure techniques were employed. The average surgical pro
cedure time was 85.9 ± 43.0 min (mean ± standard deviation, Table 3),
and the majority of the patients did not require a drain (n = 115, 95.8%).
When a drain was placed, the average drain duration was 15.7 ± 9.9
days (mean ± standard deviation). The average length of stay was 1.0 ±
1.4 days (mean ± standard deviation, Table 3).

Study Endpoints:

Primary: SSO
≤45-day

Secondary: SSO
>45-day

SSI, n (%)
Seroma, n (%)
Hematoma, n (%)
Wound Dehiscence, n (%)
Skin Necrosis, n (%)
Mesh Infection, n (%)
Fistula, n (%)
Other Secondary Endpoints:
Surgical procedure time, min (mean
± SD)
Length of stay, days (mean ± SD)
Hernia recurrence rate, n (%)
Reoperation rate, n (%)
Reason for Reoperation
Hernia recurrence, n
Additional procedures, n
Device-related adverse events, n (%)
(excluding recurrence)
Small bowel obstruction, n
Abdominal pain, n

0 (0.0%)
0 (0.0%)
1 (0.8%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)
0 (0.0%)

Visual Analog Scale – Pain, cm (mean
± SD)
Carolinas Comfort Scale® – Total
Score (mean ± SD)
SF-12® Physical Component Score
(mean ± SD)
SF-12® Mental Component Score
(mean ± SD)

85.9 ± 43.0
1.0 ± 1.4
38 (31.7%)
22 (18.3%)
22
2
2 (1.7%)
1
1
Baseline
1.99 ± 2.4

24 months
0.60 ± 1.5*

1.15 ± 1.1

0.17 ± 0.4*

44.4 ± 9.6

48.0 ± 9.7*

53.5 ± 9.5

52.3 ± 9.6

to sponsor (n = 1) or investigator (n = 1) decision. The patient removed
due to sponsor decision involved a mesh that was cut through, and the
patient removed due to investigator decision was placed on hospice
during the study period. As shown in Fig. 2 and Table 3, n = 38 (31.7%)
patients experienced a hernia recurrence, n = 22 (18.3%) required a
reoperation, n = 2 (1.7%) reported device-related adverse events
(excluding recurrence), and n = 8 (6.7%) had the P4HB-ST mesh
explanted at the time of reoperation. In half of the recurrences (n = 19;
50.0%), the mesh was fixated with a combination of suture and

3.4. Study endpoints
A total of n = 83 (69.2%) patients completed the 24-month follow-up
visit (Fig. 1 & Table 1). The majority of the n = 37 patients who did not
complete the study had the mesh removed or revised during reoperation
(n = 21), excluding those patients from later follow-up. A small number
of patients were lost to follow-up (n = 6), withdrew consent (n = 5), died
(n = 2), moved out of state (n = 1), or were removed from the study due
4
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Fig. 2. Kaplan-Meier curve for hernia recurrence.

mechanical fixation, while the remaining n = 12 (31.6%) and n = 7
(18.4%) were fixated with only mechanical or suture fixation,
respectively.
Visual Analog Scores (VAS) for pain decreased significantly from
1.99 ± 2.4 prior to surgery (baseline) to 0.60 ± 1.5 at 24-months
postimplantation (p < 0.05). Carolinas Comfort Scale® – Total Score
decreased significantly from 1.15 ± 1.1 prior to surgery (baseline) to
0.17 ± 0.4 at 24-months postimplantation (p < 0.05). For the SF-12v2®
scores, the Physical Component Score increased significantly from 44.4

± 9.6 prior to surgery (baseline) to 48.0 ± 9.7 at 24-months post
implantation (p < 0.05), while the Mental Component Score remained
unchanged from baseline (53.5 ± 9.5) to 24-month postimplantation
(52.3 ± 9.6; p > 0.05). Quality of life assessment values for all inter
mediate time points are shown in Fig. 3.
A single SSO was reported within the first 45 days postimplantation
(n = 1 hematoma, 0.8%; Table 3). The Kaplan-Meier estimate of SSO at
45-days follow-up was 0.8% (95% CI: 0.1%, 5.8%). There were no SSOs
requiring intervention >45 days postimplantation (0/120, 0.0%).

Fig. 3. Quality of life assessments: A) Visual Analog Scale (VAS) for Pain (mean); B) Carolinas Comfort Scale® (CCS) – Total Score (mean); C) SF-12v2® Physical
Component Score (PCS) (mean); D) SF-12v2® Mental Component Score (MCS) (mean);
*p < 0.05 (Baseline vs. 24 months).
5
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clearly warn against this practice [6].
Hernia defect area may also play a role in determining clinical out
comes such as recurrence. In this study, the majority of the defects were
small with a median area of 7.1 cm2. When recurrence rate was analyzed
at Day 730, defects <7.1 cm2 had a Kaplan-Meier hernia recurrence rate
of 18.6%, regardless of whether barbed or smooth sutures were utilized
for fascial closure. Recurrence rates were significantly and dispropor
tionately higher in defects ≥7.1 cm2 (43.3%; p = 0.019). Thus, large
defects may not be ideal for P4HB-ST when laparoscopic repair is
planned, and suture selection is critical. If the abdominal fascia is closed
with barbed suture and later fails, the repair will become a bridged
repair, leading to a high likelihood of recurrence. Interestingly, the re
sults of this study showed that suture selection is less impactful in small
defects, allowing for more flexibility with the use of fully absorbable
materials in small defects. P4HB-ST exhibited a K-M recurrence rate of
18.6% at Day 730 in defects <7.1 cm2, which is comparable to other
long-term studies of both fully absorbable and permanent meshes [10,
21,30,31]. Thus, P4HB-ST may be better suited for small defects.

Hernia-related complications were graded according to the ClavienDindo system and are depicted in Supplementary Table 1 [14].
4. Discussion
This prospective, multicenter, single-arm, open-label study evalu
ated P4HB-ST mesh in LIVHR in patients with Class I (clean) wounds at
high risk for SSO and represents the first clinical trial associated with
this material in LIVHR. There is a previous trial reporting positive out
comes with the use of P4HB-ST at the hiatus during laparoscopic para
esophageal hernia repair [15], as well as favorable long-term data on the
use of P4HB in the retrorectus space [10]. There are several interesting
findings in our study. As expected, there was a low rate of SSO and
device-related complications, with improvement in quality of life scores
when utilizing P4HB-ST mesh in a minimally invasive approach to
LIVHR. Similar outcomes have been documented in other large series
with long-term follow-up [16]. The 31.7% hernia recurrence rate
observed in this study was higher than previously reported 17.9% and
11% for open VHR with P4HB mesh [10,11]. However, recurrence in
LIVHR is notoriously variable, ranging from 1% up to 29% in other se
ries [17–21], with a variety of mesh types and patient factors contrib
uting to these outcomes.
It is a common tenet in open ventral hernia repair that mesh rein
forcement of fascial closure results in the best long-term results
compared to a bridged repair [22,23]. Closure of fascia in minimally
invasive surgery has been a recent topic of debate, as initially laparo
scopic repairs were bridged repairs [16]. Recently, several studies have
reported improvement in outcomes in patients undergoing defect
closure in laparoscopic and robotic ventral hernia repair [24–26]. One of
the inclusion criteria for this trial was fascial closure. As there have been
good long-term outcomes associated with the P4HB material in open
ventral hernia with low recurrence rates [10,11], it is possible that the
higher recurrence rate in this trial was related to the nuances of fascial
closure in minimally invasive repair compared to open repair. It should
also be acknowledged that meshes were placed in the retrorectus or
onlay position in studies utilizing an open technique, which is a different
tissue plane than the current study. Tissue plane and fascial closure
technique may both play a role.
One of the issues with fascial closure for laparoscopic ventral hernia
repair is that suturing can be technically challenging, especially with
large defects under tension. Techniques have been described to facilitate
fascial closure in LIVHR, including the so called “shoelacing” technique
[27]. Recently, robotic technology has been touted to improve the
ability to close fascial defects in minimally invasive hernia repair
compared to laparoscopic repair [26]. While there are some adjuncts
that are improving the ability to close fascial defects in a minimally
invasive manner, it is likely that this closure may not be as robust as
when done open under direct visualization, and perhaps this is why
there is some discrepancy in the recurrence rates.
Furthermore, when a fully absorbable material such as P4HB-ST is
utilized to repair a hernia defect, effective fascial closure is critical.
Slightly more than half of the patients in this study received barbed
suture to close the fascia (n = 66; 55%; data not shown). Out of a total of
n = 38 recurrences observed in this trial, 61% (n = 23; data not shown)
occurred when barbed suture was used to close the fascia. Many types of
barbed sutures have not been indicated for fascial closure. Compared to
traditional, smooth sutures, the diameter of a barbed suture is reduced
and the core weakened when the barbs are cut into the suture during the
manufacturing process [28]. If barbed sutures are used for fascial closure
and prematurely release from the fascia, the implanted P4HB-ST mesh
will essentially function as a bridged repair. Other fully absorbable
materials such as biological tissue-derived meshes have exhibited
extremely high recurrence rates, reaching 80% in some series, when
utilized to bridge a hernia defect [29]. Similar results would be expected
for a fully absorbable synthetic material such as P4HB-ST mesh under
bridging conditions, and the Instructions for Use for P4HB-ST mesh

5. Conclusions
P4HB-ST mesh demonstrated low rates of SSO and device-related
complications, with improved quality of life scores, and reoperation
rate comparable to other published studies [10,11,19–21]. Recurrence
rate was higher than expected at 31.7%. However, when analyzed by
hernia defect size, recurrence was disproportionately high in defects
≥7.1 cm2 (43.3%) compared to defects <7.1 cm2 (18.6%). Thus, in
LVIHR, P4HB-ST may be better suited for small defects. Caution is
warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger
defects until additional studies can further investigate outcomes.
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Registration of research studies

Appendix A. Supplementary data

Name of the registry: Clinical Trials.gov.
Unique Identifying number or registration ID: NCT02712398.
Hyperlink to your specific registration (must be publicly accessible
and will be checked): https://clinicaltrials.gov/ct2/show/NCT027123
98?term=02712398&draw=2&rank=1.

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.amsu.2021.103156.
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